ProCE Banner Series

Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors

Join us for this engaging, CME-certified live symposium at ASH 2024 on the optimal use of BTK inhibitors in mantle cell lymphoma. Explore expert insights on approved therapies and emerging treatment strategies with BTK inhibitors and participate in discussions with our panel of specialists.

Friday Satellite Symposium on "Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors," preceding the 66th ASH Annual Meeting and Exposition. 

  AMA
Who Should Attend

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with mantle cell lymphoma.

All Events

Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors

Past Events

December

06

2024

11:00 AM - 1:15 PM Pacific Time (PT)

In-person

Manchester Grand Hyatt San Diego, 1 Market Place, San Diego, California 92101

11:30 AM - 1:15 PM Pacific Time (PT)

Virtual

Faculty

ProCE Banner Faculty
Brad Kahl, MD

Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St. Louis, Missouri

ProCE Banner Faculty
John P. Leonard, MD

Senior Associate Dean for Innovation and Initiatives
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine
NewYork-Presbyterian
New York, New York

ProCE Banner Faculty
Julie M. Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Mantle cell lymphoma (MCL).

Target Audience
This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with mantle cell lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply recent data, safety profiles, and expert opinion to the selection of BTK inhibitor based combinations in treatment-naïve mantle cell lymphoma
  • Use recommended, evidence-based approaches to address adverse events associated with BTK inhibitor therapy in patients with B-cell lymphomas
  • Assess patients for challenges to adherence and persistence to prescribed BTK inhibitor regimens in mantle cell lymphoma
  • Evaluate evidence for current and emerging treatment options for patients with relapsed/refractory MCL following treatment with BTK inhibitors in the treatment naïve setting

Accreditation

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from AstraZeneca.